Payment overview · 2025
General Payments
$1,890.71
80 reported records · 19 companies
Healthcare provider profile · identity verified
John P Wagner, DO
Allopathic & Osteopathic Physicians|Family Medicine · STOW, OH · NPI 1104869080
Verified facts
What the public records show
CMS Open Payments records show John P Wagner, DO received $1,890.71 in general payments during 2025 across 80 reported records.
Novo Nordisk Inc accounted for 14.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 829 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $263.85 | 14.0% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $254.95 | 13.5% | 12 | 2025 |
| FEMSelect Inc. | Unresolved — no canonical attribution shown | $237.81 | 12.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.71 | 9.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $171.34 | 9.1% | 12 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $149.98 | 7.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $145.25 | 7.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $94.84 | 5.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $79.57 | 4.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $72.60 | 3.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.90 | 3.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.58 | 1.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.70 | 1.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.62 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.17 | 1.3% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.17 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.27 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.89 | 0.9% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $15.51 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,890.71 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENPLACE Normalized: enplace |
Device | FEMSelect Inc. | $237.81 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $223.81 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $217.33 | 20 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $203.82 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $174.41 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $172.71 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $149.98 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $145.25 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $136.76 | 10 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $72.60 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.52 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.50 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.58 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.58 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $31.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.70 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| NUVARING Normalized: nuvaring |
Drug | Organon LLC | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 829 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 156 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
120 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
211 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
829 | 118 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1317 | 225 |
| Levothyroxine Sodium | Levothyroxine Sodium | 879 | 166 |
| Eliquis | Apixaban | 829 | 118 |
| Sertraline Hcl | Sertraline Hcl | 790 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 710 | 139 |
| Pantoprazole Sodium | Pantoprazole Sodium | 692 | 133 |
| Furosemide | Furosemide | 633 | 143 |
| Mirtazapine | Mirtazapine | 580 | 98 |
| Gabapentin | Gabapentin | 556 | 100 |
| Potassium Chloride | Potassium Chloride | 544 | 96 |
| Metoprolol Tartrate | Metoprolol Tartrate | 538 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 512 | 96 |
| Trazodone Hcl | Trazodone Hcl | 468 | 93 |
| Donepezil Hcl | Donepezil Hcl | 458 | 74 |
| Lisinopril | Lisinopril | 455 | 89 |
| Clopidogrel | Clopidogrel Bisulfate | 390 | 63 |
| Losartan Potassium | Losartan Potassium | 384 | 76 |
| Carvedilol | Carvedilol | 354 | 59 |
| Divalproex Sodium | Divalproex Sodium | 339 | 53 |
| Omeprazole | Omeprazole | 335 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 327 | 60 |
| Memantine Hcl | Memantine Hcl | 325 | 64 |
| Spironolactone | Spironolactone | 283 | 45 |
| Metformin Hcl | Metformin Hcl | 280 | 48 |
| Risperidone | Risperidone | 272 | 34 |
| Famotidine | Famotidine | 262 | 46 |
| Buspirone Hcl | Buspirone Hcl | 256 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 238 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 238 | 44 |
| Montelukast Sodium | Montelukast Sodium | 232 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 222 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 216 | 36 |
| Levetiracetam | Levetiracetam | 215 | 25 |
| Xarelto | Rivaroxaban | 211 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 43 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 188 | 60 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 187 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 33 |
| Jardiance | Empagliflozin | 156 | 16 |
| Torsemide | Torsemide | 155 | 37 |
| Allopurinol | Allopurinol | 148 | 25 |
| Finasteride | Finasteride | 146 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 135 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 131 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 52 |
| Warfarin Sodium | Warfarin Sodium | 128 | 13 |
| Olanzapine | Olanzapine | 124 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 124 | 24 |
| Lactulose | Lactulose | 121 | 15 |
| Myrbetriq | Mirabegron | 120 | 16 |
| Bupropion Xl | Bupropion Hcl | 118 | 22 |
| Baclofen | Baclofen | 117 | 22 |
| Topiramate | Topiramate | 116 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 115 | 26 |
| Alendronate Sodium | Alendronate Sodium | 109 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 105 | 35 |
| Latanoprost | Latanoprost | 104 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 103 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 73 |
| Aripiprazole | Aripiprazole | 98 | 17 |
| Simvastatin | Simvastatin | 98 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 23 |
| Cimetidine | Cimetidine | 94 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 94 | 23 |
| Cephalexin | Cephalexin | 93 | 53 |
| Bumetanide | Bumetanide | 91 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 91 | 19 |
| Clonidine Hcl | Clonidine Hcl | 90 | suppressed |
| Meloxicam | Meloxicam | 90 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 19 |
| Lorazepam | Lorazepam | 89 | 40 |
| Ezetimibe | Ezetimibe | 88 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 87 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 44 |
| Entresto | Sacubitril/Valsartan | 81 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 16 |
| Prednisone | Prednisone | 77 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 73 | 47 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 72 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 13 |
| Lamotrigine | Lamotrigine | 70 | suppressed |
| Haloperidol | Haloperidol | 64 | 11 |
| Rivastigmine | Rivastigmine | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 63 | suppressed |
| Nystatin | Nystatin | 63 | 33 |
| Glipizide | Glipizide | 60 | suppressed |
| Clozapine | Clozapine | 59 | suppressed |
| Ibuprofen | Ibuprofen | 58 | 14 |
| Insulin Lispro | Insulin Lispro | 58 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 15 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 57 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 11 |
| Humalog | Insulin Lispro | 54 | 16 |
| Digoxin | Digoxin | 53 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | suppressed |
| Loperamide | Loperamide Hcl | 51 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 11 |
| Budesonide | Budesonide | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 22 |
| Calcitriol | Calcitriol | 48 | suppressed |
| Linzess | Linaclotide | 48 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 23 |
| Sucralfate | Sucralfate | 48 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 47 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | suppressed |
| Glimepiride | Glimepiride | 46 | suppressed |
| Xifaxan | Rifaximin | 46 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 45 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 44 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 14 |
| Tramadol Hcl | Tramadol Hcl | 43 | 16 |
| Kapspargo Sprinkle | Metoprolol Succinate | 42 | suppressed |
| Lovastatin | Lovastatin | 42 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 42 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 32 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 25 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 39 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 38 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Metolazone | Metolazone | 37 | suppressed |
| Brilinta | Ticagrelor | 36 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | 14 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 13 |
| Morphine Sulfate | Morphine Sulfate | 35 | 29 |
| Zonisamide | Zonisamide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 34 | 16 |
| Ziprasidone Hcl | Ziprasidone Hcl | 34 | suppressed |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 33 | suppressed |
| Paliperidone Er | Paliperidone | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 12 |
| Daptomycin | Daptomycin | 30 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 30 | 20 |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 18 |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Anastrozole | Anastrozole | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Calcium Acetate | Calcium Acetate | 25 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Klayesta | Nystatin | 24 | 21 |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 15 |
| Hydrocortisone | Hydrocortisone | 23 | 13 |
| Methimazole | Methimazole | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 22 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 22 | suppressed |
| Nadolol | Nadolol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | suppressed |
| Nystop | Nystatin | 21 | 12 |
| Atenolol | Atenolol | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Budesonide Ec | Budesonide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 14 |
| Dofetilide | Dofetilide | 18 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 18 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 18 | 18 |
| Cilostazol | Cilostazol | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | 16 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | 14 |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Meropenem | Meropenem | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | 12 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Lamotrigine Odt | Lamotrigine | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sirolimus | Sirolimus | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,890.71 · 80 records | Novo Nordisk Inc | AREXVY, BEXSERO, BREZTRI, BRIUMVI, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, ENPLACE, GARDASIL 9, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NEXPLANON, NURTEC ODT, NUVARING, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VYALEV, Veozah, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error